Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Herve Affagard | CEO, Co-Founder & Director | 403.79k | -- | 1975 |
| Dr. Joel Dore Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Mr. Pierre Rimbaud | Co-Founder | -- | -- | -- |
| Mr. Eric Soyer Ph.D. | Chief Financial Officer | -- | -- | 1966 |
| Ms. Carole Schwintner | Technology Director & Chief Technology Officer | -- | -- | -- |
| Dr. Nathalie Corvaia Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Guilhaume Debroas Ph.D. | Head of Investor Relations | -- | -- | -- |
| Ms. Sian Crouzet | Chief of Staff | -- | -- | -- |
| Dr. Emilie Plantamura | Head of Clinical Development | -- | -- | -- |
| Mr. Jonathan Chriqui Pharm.D. | Chief Business Officer | -- | -- | -- |
MaaT Pharma SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 54
Description
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available